JP2021523159A5 - - Google Patents
Info
- Publication number
- JP2021523159A5 JP2021523159A5 JP2020562751A JP2020562751A JP2021523159A5 JP 2021523159 A5 JP2021523159 A5 JP 2021523159A5 JP 2020562751 A JP2020562751 A JP 2020562751A JP 2020562751 A JP2020562751 A JP 2020562751A JP 2021523159 A5 JP2021523159 A5 JP 2021523159A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- hydroxyl
- independently
- alkoxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024007265A JP7810734B2 (ja) | 2018-05-08 | 2024-01-22 | Ｅｒｂｂ受容体阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/085998 | 2018-05-08 | ||
| CN2018085998 | 2018-05-08 | ||
| PCT/CN2019/085949 WO2019214634A1 (en) | 2018-05-08 | 2019-05-08 | Erbb receptor inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024007265A Division JP7810734B2 (ja) | 2018-05-08 | 2024-01-22 | Ｅｒｂｂ受容体阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523159A JP2021523159A (ja) | 2021-09-02 |
| JP2021523159A5 true JP2021523159A5 (https=) | 2022-05-13 |
| JP7540953B2 JP7540953B2 (ja) | 2024-08-27 |
Family
ID=68467752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562751A Active JP7540953B2 (ja) | 2018-05-08 | 2019-05-08 | Ｅｒｂｂ受容体阻害剤 |
| JP2024007265A Active JP7810734B2 (ja) | 2018-05-08 | 2024-01-22 | Ｅｒｂｂ受容体阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024007265A Active JP7810734B2 (ja) | 2018-05-08 | 2024-01-22 | Ｅｒｂｂ受容体阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10822334B2 (https=) |
| EP (2) | EP4410291A3 (https=) |
| JP (2) | JP7540953B2 (https=) |
| KR (1) | KR102806778B1 (https=) |
| CN (4) | CN112266384B (https=) |
| AR (1) | AR117424A1 (https=) |
| AU (1) | AU2019267959B2 (https=) |
| BR (1) | BR112020022829A2 (https=) |
| CA (1) | CA3099315A1 (https=) |
| DK (1) | DK3814341T3 (https=) |
| ES (1) | ES2977196T3 (https=) |
| MX (2) | MX2020011868A (https=) |
| PT (1) | PT3814341T (https=) |
| TW (2) | TWI858848B (https=) |
| WO (1) | WO2019214634A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| WO2019196622A1 (zh) * | 2018-04-09 | 2019-10-17 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| TWI858848B (zh) * | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| EP4523755A3 (en) * | 2018-09-18 | 2025-06-11 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| TWI879751B (zh) * | 2020-03-23 | 2025-04-11 | 印度商皮埃企業有限公司 | 3-被取代的苯基脒化合物及其製備和用途 |
| CA3194724A1 (en) * | 2020-10-05 | 2022-04-14 | Dana-Farber Cancer Institute, Inc. | Potent and selective inhibitors of her2 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| IL312004A (en) * | 2021-10-20 | 2024-06-01 | Hoffmann La Roche | Crystalline forms of quinazoline derivatives, their preparation, assembly and use |
| CN114262327B (zh) * | 2021-12-30 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
| CN114671867B (zh) * | 2022-03-15 | 2023-09-19 | 上海法默生物科技有限公司 | 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法 |
| CN118715216A (zh) * | 2022-03-28 | 2024-09-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| AU2023329558A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023410324A1 (en) | 2022-12-22 | 2025-05-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
| CN116102491A (zh) * | 2023-02-17 | 2023-05-12 | 浙江晖石药业有限公司 | 一种利用连续流技术进行金属催化偶联的应用 |
| TW202446386A (zh) * | 2023-04-14 | 2024-12-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 喹唑啉ＥｒｂＢ抑制劑的藥物形式 |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| CN121568696A (zh) | 2023-07-28 | 2026-02-24 | 勃林格殷格翰国际有限公司 | 制备her2抑制剂的方法 |
| WO2025051148A1 (zh) * | 2023-09-05 | 2025-03-13 | 北京鞍石生物科技股份有限公司 | 含氮杂芳基化合物及其制备方法和应用 |
| CN117534669A (zh) * | 2023-11-01 | 2024-02-09 | 上海凌凯医药科技有限公司 | 五元氮杂环并吡啶醇的制备方法 |
| CN117658818B (zh) * | 2023-11-03 | 2025-02-07 | 江西巍华化学有限公司 | 一种4-氟-3-硝基三氟甲苯的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US20050043336A1 (en) * | 2001-11-03 | 2005-02-24 | Hennequin Laurent Francois Andre | Quinazoline derivatives as antitumor agents |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CN101273033A (zh) * | 2005-09-20 | 2008-09-24 | 阿斯利康(瑞典)有限公司 | 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物 |
| ATE488513T1 (de) * | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
| ATE446294T1 (de) * | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| TWI858848B (zh) | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
-
2019
- 2019-05-07 TW TW112129260A patent/TWI858848B/zh active
- 2019-05-07 TW TW108115721A patent/TWI811358B/zh active
- 2019-05-07 AR ARP190101206A patent/AR117424A1/es unknown
- 2019-05-08 AU AU2019267959A patent/AU2019267959B2/en active Active
- 2019-05-08 KR KR1020207034917A patent/KR102806778B1/ko active Active
- 2019-05-08 JP JP2020562751A patent/JP7540953B2/ja active Active
- 2019-05-08 CN CN202010657663.6A patent/CN112266384B/zh active Active
- 2019-05-08 MX MX2020011868A patent/MX2020011868A/es unknown
- 2019-05-08 WO PCT/CN2019/085949 patent/WO2019214634A1/en not_active Ceased
- 2019-05-08 CA CA3099315A patent/CA3099315A1/en active Pending
- 2019-05-08 EP EP24164213.1A patent/EP4410291A3/en active Pending
- 2019-05-08 CN CN202010656946.9A patent/CN111747953B/zh active Active
- 2019-05-08 CN CN202010657654.7A patent/CN111662289A/zh active Pending
- 2019-05-08 DK DK19800509.2T patent/DK3814341T3/da active
- 2019-05-08 PT PT198005092T patent/PT3814341T/pt unknown
- 2019-05-08 ES ES19800509T patent/ES2977196T3/es active Active
- 2019-05-08 EP EP19800509.2A patent/EP3814341B1/en active Active
- 2019-05-08 BR BR112020022829-0A patent/BR112020022829A2/pt active Search and Examination
- 2019-05-08 CN CN201980006431.XA patent/CN111587248A/zh active Pending
-
2020
- 2020-06-24 US US16/910,267 patent/US10822334B2/en active Active
- 2020-09-23 US US17/029,074 patent/US11447492B2/en active Active
- 2020-11-06 MX MX2023008954A patent/MX2023008954A/es unknown
-
2024
- 2024-01-22 JP JP2024007265A patent/JP7810734B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523159A5 (https=) | ||
| ES2925564T3 (es) | Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos | |
| TWI826416B (zh) | 趨化介素受體調節劑及其用途 | |
| ES2761824T3 (es) | Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa | |
| US10246462B2 (en) | Chemokine receptor modulators and uses thereof | |
| CN116283647A (zh) | 整合应激通路的前药调节剂 | |
| TW202016082A (zh) | 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法 | |
| CN112154142A (zh) | 整合应激通路的调节剂 | |
| AU2018360855A1 (en) | Modulators of the integrated stress pathway | |
| JP2019518741A5 (https=) | ||
| JP2011519941A5 (https=) | ||
| JP2020506951A5 (https=) | ||
| JP2016501223A (ja) | アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト | |
| JP2025061387A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| TW202406902A (zh) | 趨化介素受體調節劑及其用途 | |
| US20260041693A1 (en) | Combination therapy of cdk7 inhibitors with other anti-cancer therapies | |
| TW202340142A (zh) | Ｇｃｌ抑制劑 | |
| RU2020138336A (ru) | Ингибиторы рецепторов erbb | |
| CN121399105A (zh) | 杂芳族dhodh抑制剂 | |
| BR112019001732B1 (pt) | Moduladores de receptor de quimiocina e usos dos mesmos | |
| BR122025024077A2 (pt) | Moduladores de receptor de quimiocina e usos dos mesmos | |
| HK40044910A (en) | Modulators of the integrated stress pathway |